Authors
Latest:
Dr. Bryan Mehlhaff on PSA's Role in Prostate CancerBryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
Latest:
Dr. Haugen Describes the 82nd Annual ATA MeetingDr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.
Latest:
Dr Schneider on Targeted Treatment Options in MET Exon 14 Mutated–NSCLCBryan Schneider, MD, discusses agents available for use in the targeting of MET exon 14 mutations in non–small cell lung cancer.
Latest:
Managing Chemotherapy-Induced Peripheral NeuropathyChemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.
Latest:
Making the Move to ExerciseAmy Hoffman, MSN, PhD, RN, from Michigan State University's College of Nursing, offers practical tips to help initiate a regular exercise strategy for cancer patients and survivors.
Latest:
Does Lifestyle Matter to Prevent Cancer or Is It Just All “Bad Luck”?We now have a better understanding of the sequence of events, particularly regarding the timing of these mutations, their impact, and some of the factors involved that might cause them.
Latest:
Clinical Next-Generation Sequencing to Guide Cancer Treatment DecisionsIn the past year, clinical laboratories have begun determining the tumor mutational status of multiple genes simultaneously using next-generation sequencing platforms.
Latest:
Improving Practice Efficiency Through Emerging TechnologiesThe New Year offers little hope of breakthrough software improvements for medical practices, but experts say oncologists can still make 2015 a time of breakthrough productivity gains.
Latest:
Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor TypesOncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.
Latest:
Improving Cancer Survivorship: Embedding Tailored, Comprehensive Survivorship Care in the Breast Oncology ClinicAnn Partridge, MD, MPH, from Dana-Farber Cancer Institute and Sandy Truong, a Harvard Medical School student, discuss the needs of cancer survivors and their efforts to optimize survivorship care.
Latest:
Neurosurgical Innovations Advance Safe Resection of Difficult Brain TumorsArnold B. Etame, MD, PhD, from the Moffitt Cancer Center, describes stereotactic neuronavigation, which may offer more surgical visualization capabilities for the neurosurgeon.
Latest:
Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or SarcomaArta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.
Latest:
ASH 2010: Data Support Escalated BEACOPP as Superior Method of Tumor Control in Early Unfavorable Hodgkin LymphomaIn patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.
Latest:
Preparing Nurses for Advanced Practice in Oncology and Palliative CareBarbara Daly, PhD, RN, FAAN, and Helen Foley, MSN, AOCNS®, offer highlights of their institution's oncology and palliative care program, which successfully prepares graduates to assume advanced practice roles in these important areas.
Latest:
USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical PracticeBarbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.
Latest:
T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast CancerT-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.
Latest:
Where Do We Go from Here? A Health 2.0 Progress ReportHealthcare consumers may be the driving force behind Health 2.0, but are they really in control? And who knows what the final destination will be?
Latest:
Mindfulness Based Resilience and Self-Care: Why it Matters in OncologyThe Buddhist teaching that "Your true work is to discover your world and then with all your heart give yourself to it" can certainly be applied to oncology.
Latest:
Home Sales: It%u2019s A Buyer%u2019s MarketThis year, most Americans have seen the value of their home drop faster than a lead weight. If you purchased your home in the last 10 years, during the housing boom, you will likely find that it is worth less today than what you paid for it%u2014and in some cases less than what you still owe.
Latest:
Personalized Medicine Is Gaining Momentum in Advanced Endometrial CancerMolecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.
Latest:
Optimizing Outcomes With ADCs in Breast Cancer Requires a Tactical ApproachAntibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.
Latest:
Sequencing VEGFR-Targeted and mTOR-Targeted Therapy in Advanced Renal Cell CarcinomaWith 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.
Latest:
The Importance of Mentoring in Preparing the Next Generation of OncologistsSince the time of Hippocrates, practicing the art of medicine has involved the passage of knowledge and experience from one generation of practitioners to the next.
Latest:
The Rapid Reporter: April 2007This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).
Latest:
ImmunotherapyNovel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.
Latest:
Aggressive Goals Fuel Research, Growth at 'The James'The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute opened on July 9, 1990,as the adult patient-care component of The Ohio State University (OSU) Comprehensive Cancer Center (CCC).Today, "The James," as it is referred to, is the only dedicated cancer hospital in the Midwest.
Latest:
Integrative Medicine and Cancer TreatmentLinda A. Lee, MD, director of the Johns Hopkins Integrative Medicine & Digestive Center (JHIMDC) in Lutherville, Maryland, believes that an integrative approach to treating conditions and symptoms helps improve patients' quality of life.
Latest:
Are Your Patients in Clinical Trials? US Oncology Surveys OncologistsParticipation in clinical trial research is essential to continued improvement in cancer care. Yet, fewer than 10% of U.S. adults enroll in trials. A recent US Oncology�sponsored survey found that most oncologists remain optimistic about the future of clinical trial research. We discuss obstacles to clinical trial enrollment with Nicholas Vogelzang, MD, and Matthew Galsky, MD, of the Comprehensive CancerCenters of Nevada.
Latest:
Flash FindingsFast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer
